Effects of anaerobic training in children with cystic fibrosis: a randomized controlled study

Peter H C Klijn1, Annemarie Oudshoorn, Cornelis K van der Ent

  • 1Department of Pediatric Physical Therapy, Wilhelmina Children's Hospital, University Medical Center, Utrecht, the Netherlands.

Chest
|April 14, 2004
PubMed

Insights

Anaerobic training significantly improved anaerobic performance and quality of life in children with cystic fibrosis (CF). These benefits were sustained after a 12-week follow-up, suggesting its therapeutic potential.

Area of Science:

  • Pediatric Exercise Science
  • Respiratory Medicine
  • Rehabilitation Therapy

Background:

  • Children's physical activity is predominantly anaerobic.
  • Anaerobic exercise in pediatric cystic fibrosis (CF) is understudied.
  • Investigated anaerobic training effects in children with CF.

Purpose of the Study:

  • To assess the impact of a 12-week anaerobic training program on children with CF.
  • To evaluate changes in body composition, pulmonary function, muscle force, and exercise performance.
  • To determine the sustainability of training effects during a 12-week follow-up period.

Main Methods:

  • Twenty children with CF were randomized into a training group (TG, n=11) or control group (CG, n=9).
  • The TG underwent 12 weeks of anaerobic training (2 days/week, 30-45 min/session).
  • Assessed outcomes included body composition, pulmonary function, muscle force, aerobic/anaerobic performance, and quality of life.

Main Results:

  • The TG showed significant improvements in anaerobic performance, aerobic performance, and quality of life.
  • No significant changes were observed in the CG.
  • Post-follow-up, the TG maintained significantly higher anaerobic performance and quality of life compared to baseline.

Conclusions:

  • Anaerobic training positively impacts anaerobic performance and quality of life in children with CF.
  • Aerobic performance improvements were observed but not sustained post-training.
  • Anaerobic training is a valuable addition to therapeutic strategies for pediatric CF patients.
Abstract